Sumant Ramachandra - 21 Mar 2025 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role: Director
Signature: /s/ Matthew Lang, as Attorney-in-Fact
Issuer symbol: LYEL
Transactions as of: 21 Mar 2025
Net transactions value: +$115,220
Form type: 4
Filing time: 25 Mar 2025, 18:46:17 UTC
Previous filing: 01 Nov 2024
Next filing: 19 May 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LYEL	Common Stock	Purchase	$115,220	+200,000		$0.5761	200,000	21 Mar 2025	Grantor and Trustee	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.5487 to $0.5879, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range.
F2	Shares held by the Sumant Ramachandra Rev Trust DTD 01/24/12. The Reporting Person is grantor and trustee of the Sumant Ramachandra Rev Trust DTD 01/24/12.

Content

The price reported above reflects the weighted average price of the shares purchased. These shares were purchased in multiple transactions at prices ranging from $0.5487 to $0.5879, inclusive. Upon request from the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this range.

Shares held by the Sumant Ramachandra Rev Trust DTD 01/24/12. The Reporting Person is grantor and trustee of the Sumant Ramachandra Rev Trust DTD 01/24/12.